IOBT Insider Trading Activity and SEC Form 4 Filings
IOBT insider trading summary
No open-market insider purchases or sales of IO Biotech, Inc. (IOBT) have been reported on SEC Form 4 in the past 12 months.
Latest IOBT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 30, 2025 | Heidi Hunter | Insider | Buy | $21K (15,000 @ $1.39) |
| Dec 23, 2024 | Amy Sullivan | Chief Financial Officer | Buy | $8K (10,250 @ $0.83) |
| Dec 23, 2024 | Devin Whittemore Smith | General Counsel | Buy | $10K (12,000 @ $0.81) |
| Dec 23, 2024 | Mai-Britt Zocca | Chief Executive Officer | Buy | $10K (12,500 @ $0.81) |
| Dec 23, 2024 | Qasim Iftikhar Ahmad | Chief Medical Officer | Buy | $27K (31,350 @ $0.85) |
| Jul 26, 2024 | Novo Holdings A/S | Insider | Sell | $31K (23,478 @ $1.31) |
| Jul 25, 2024 | Novo Holdings A/S | Insider | Sell | $68K (51,522 @ $1.33) |
| May 10, 2024 | Novo Holdings A/S | Insider | Sell | $802K (658,809 @ $1.22) |
| Feb 9, 2024 | Novo Holdings A/S | 10% Owner | Sell | $988K (658,809 @ $1.50) |
| Nov 22, 2023 | Brian Burkavage | Chief Accounting Officer | Buy | $5K (5,000 @ $1.03) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.